Nuveen LLC Takes Position in Fractyl Health, Inc. $GUTS

Nuveen LLC purchased a new stake in shares of Fractyl Health, Inc. (NASDAQ:GUTS) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 72,958 shares of the company’s stock, valued at approximately $87,000. Nuveen LLC owned 0.15% of Fractyl Health as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Nuveen Asset Management LLC lifted its stake in shares of Fractyl Health by 61.5% during the fourth quarter. Nuveen Asset Management LLC now owns 72,958 shares of the company’s stock valued at $150,000 after acquiring an additional 27,778 shares during the period. Jane Street Group LLC grew its holdings in Fractyl Health by 125.8% during the 4th quarter. Jane Street Group LLC now owns 22,700 shares of the company’s stock worth $47,000 after acquiring an additional 12,648 shares during the period. Bank of New York Mellon Corp grew its holdings in Fractyl Health by 54.5% during the 1st quarter. Bank of New York Mellon Corp now owns 64,020 shares of the company’s stock worth $76,000 after acquiring an additional 22,572 shares during the period. Raymond James Financial Inc. acquired a new stake in Fractyl Health during the 4th quarter worth $34,000. Finally, Northstar Financial Companies Inc. acquired a new stake in Fractyl Health during the 4th quarter worth $140,000.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Canaccord Genuity Group cut their target price on Fractyl Health from $12.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, August 14th. LADENBURG THALM/SH SH assumed coverage on Fractyl Health in a research note on Thursday, August 28th. They issued a “buy” rating and a $3.60 target price on the stock. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $6.53.

Fractyl Health Price Performance

Shares of GUTS stock opened at $0.92 on Monday. The firm has a market capitalization of $46.41 million, a price-to-earnings ratio of -0.45 and a beta of 1.58. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 4.61. The firm has a fifty day moving average of $1.38 and a 200-day moving average of $1.48. Fractyl Health, Inc. has a 12-month low of $0.83 and a 12-month high of $3.50.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.16). Fractyl Health had a negative return on equity of 584.35% and a negative net margin of 73,864.52%. On average, equities research analysts forecast that Fractyl Health, Inc. will post -1.61 earnings per share for the current year.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.